André and colleagues showed that monalizumab can potentiate other ICI in a combination therapy, such as anti-PD-1/PD-L1 [27] and Van Montfoort and colleagues demonstrated efficacy in combination with cancer vaccines [26]. The gene discussed is PDCD1; the disease is cancer.